comparemela.com

Latest Breaking News On - Yu xuefeng - Page 8 : comparemela.com

China CanSinoBIO s COVID-19 vaccine trials recruit over 20,000 people

By Reuters Staff BEIJING (Reuters) – China’s CanSino Biologics Inc. has recruited over 20,000 participants for late-stage human trials overseas for its coronavirus vaccine, a health official said on Monday. The candidate, known as Ad5-nCoV or Convidecia, which CanSinoBIO is jointly developing with a research institute backed by the Chinese military, is among the five vaccines China has moved into Phase 3 clinical trials to test their efficacy. “As for now, the number of recruited participants has exceeded 20,000 people, and the progress is relatively fast,” said Zheng Zhongwei, an official at China’s National Health Commission, told a press conference. Phase 3 trials for CanSinoBIO’s candidate, which are planned to involve 40,000 participants in total, have begun enrolling participants in Pakistan, Russia, Mexico and Chile, the latest clinical trial registration data showed. https://bit.ly/3mHzt8R

China s vaccine gambit

Science s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation Beijing-based Sinovac, which makes a COVID-19 vaccine from inactivated virus, has efficacy trials underway in Brazil, Turkey, and Indonesia but not in China. PHOTO: REUTERS/THOMAS PETER The first people in the world to receive a COVID-19 vaccine were not part of a clinical trial. No TV stations or newspapers covered the historic event. No company issued a statement. On 29 February, less than 2 months after the world awakened to the threat of the new disease, virologist Chen Wei, a major general in China s army, and six military scientists on her team stood in front of a Chinese Communist Party flag and received injections of an experimental COVID-19 vaccine. Chen, a national hero for her work on Ebola vaccines, had come to the initial center of the pandemic, Wuhan, with her group from the Academy of Medical Military Sciences, in part to help make the candidate vaccine with pharmaceu

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.